SAT0051 CITRULLINATION OF ADENOSINE DEAMINASE ISOFORMS IN

RHEUMATOID ARTHRITIS
Background: One of the most important discoveries in rheumatology is the characterization of citrulline containing auto-antigens [1] . The identification of citrullinated proteins as auto-antigens and the development of new assay based on the detection of anti-citrullinated protein antibodies (ACPAs) become a breakthrough in the diagnosis and treatment of rheumatoid arthritis (RA). Mitsui and coauthors in vitro identified adenosine deaminase (ADA) as an ACPA antigen [2] . Earlier we have reported the enhance of ADA activity in synovial fluids (SFs) of RA patients [3] .This increasing was in correlation with the ratio of small isoenzyme (SADA) to the large (LADA) [4] .The comparison of citrullination states of SADA and LADA can be a clue for understanding the mechanism of SADA/LADA increase in RA, which is important both in diagnosis and treatment of the disease. Objectives: The objectives of this study were a) to separate SADA and LADA isoforms from SFs of RA patients and b) to compare their citrullination degree. Methods: The SADA and LADA isoforms from SFs of RA patients were separated and purified using gel-filtration and ion-exchange chromatography [4] . The citrullination degree of the isoforms was measured in the colorimetric assay with diacetylmonoxime (DAMO) [6] using the absorbance at 530 nm and free L-citrulline as a standard. Results: The SF samples of 20 RA patients with initial ADA activity in the range 35-190 IU/L were used. Earlier we demonstrated a negligible level of SADA at initial ADA lower of this interval. In the samples with medium initial activity (35-55 IU/L), SADA/LADA ratio was ≈ 1/2. In those with high ADA activity (100-190 IU/L) this ratio was ≈ 4. The separation and purification of LADA from 10 SFs revealed that it is not citrullinated in any case. In SADA from SFs with medium ADA activity, we failed to register the citrullination. In SADA from SFs with the initial ADA activity ≥100 IU/L, the significant citrullination (≈ 0.6 μmol/mg of protein) was registered.
Conclusions:
The obtained results evidence that SADA from SFs with high ADA activity can serve as new citrulline containing ACPA antigen. This finding can be a base of developing new strategy (e.g. seeking specific inhibitors) for treatment of RA patients because citrullination enhances the ADA activity [2] , hampering the increase of adenosine by methotrexate. References: [1] [1] . Objectives: To evaluate the effective chance and the consequences of CDC achievement in real world practice of Early Arthritis Clinic (EAC). Methods: A total of 349 early rheumatoid arthritis (ERA) patients with a disease duration of less than 12 months were enrolled in the study. ERA patients fulfilled the 2010 ACR criteria for RA and were followed according to the treat-to-target strategy. Subjects with symptom duration less than 3 months were defined as having "very early RA" (VERA). The mean follow-up (FU) was 38.2±32.8 months. At baseline, and every three months, the ACR/EULAR core data set variables were recorded. At baseline and every year hand and foot radiographs were examined according to modified Total Sharp score (mTSS). At each visit, clinical improvement and remission were evaluated according to EULAR criteria. The achievement of CDC (28-joint Disease Activity Score using C reactive protein <2.6, Health Assessment Questionnaire <0.5 and change from baseline in mTSS ≤0.5) was assessed every year of follow-up. Results: At the twelfth month of FU 148 (42.4%) ERA patients achieved CDC, while at the time of last FU 228 (65.3%) subjects reached this target. Patients achieving CDC at the 12th month of FU were younger (p=0.05), in higher percentage male (p=0.004), and with a normal weight (body mass index, BMI <25) (p=0.003) and had a shorter disease duration, comprising a greater number of VERA (p=0.01), compared to subjects not achieving disease control. There were no differences concerning autoantibody positivity and presence of erosions at onset between the two analyzed cohorts. Adjusting the analysis for age, the variables that arose as independent predictors of CDC at the 12th month of FU were a disease duration less than 3 months [OR (95% Background: The development of predictive tools to evaluate health risks and design personalized health plans in patients with rheumatoid arthritis (RA) achieving remission still represents a major unmet need. In this perspective, the relative weight of clinical, ultrasound and immunological assessment of disease characteristics for predicting recurrence of the inflammatory process under drug-free conditions remains unclear. Objectives: To investigate the predictive value of baseline clinical remission stringency, synovial power Doppler (PD) ultrasound indices and the incident autoimmune status, as predictors of flare under drug-free conditions after a DAS28-driven treatment strategy with methotrexate (MTX) in early RA. Methods: 85 RA patients achieving stable remission and candidate to MTX withdrawal were recruited according to the following criteria: 1) introduction of MTX within 12 months from symptoms' onset, 2) at least 24 months of MTX treatment with a DAS28-driven protocol targeting low disease activity (LDA), 3) DAS28<2.6 for ≥6 months in the absence of corticosteroids. Following treatment suspension, patients were monitored at three months' intervals across 24 months through clinical, ultrasound (hands-feet-axillary lymph nodes), radiographic and immunologic screenings (ACPA-RF status, CXCL13 circulating levels [1] [2] and FACS analysis for quantification of Ki67+/regulatory T-B cell subsets). Treatment was re-introduced in case of DAS28≥3.2 or stable LDA.
Results: At baseline, 84% of the patients were in remission according to the SDAI (<3,3) with 44% of the cases showing SDAI remission and absence of PD signal in hands and feet (SDAI<3,3 and PD=0). Despite stringent remission, 48% of the patients showed an episode of flare during follow-up with a peak incidence between 6 and 9 months after drug withdrawal. With the exception of a mild protective role of SDAI remission, none of the investigated clinical and ultrasound parameters (alone or in combination) showed a significant impact on clinical evolution across 24 months. ACPA IgG levels showed instead a strong, inflammation-independent predictive value for disease recurrence, an observation that was confirmed in the overall cohort (HR: 3.39 [1.7-6.64], p=0.0006, Cox regression) and, invariably, across progressive clinical and/or ultrasound remission thresholds (SDAI remission, SDAI remission-PD=0). Sub-analyses focused on short-term events (0-6 months after DMARDs withdrawal), identified the systemic level of CXCL13 at baseline as the strongest predictor of early disease recurrence in ACPA IgG positive individuals.
The systemic immuno-type of patients in remission is the major determinant of drug-free disease recurrence, over and above drug-induced achievement of stringent clinical and ultrasonographic control of the peripheral inflammatory process. 
Methods:
We examined the clinical features of 60 RA-IP patients admitted to our hospital between July 2010 and September 2016. We compared the characteristics between patients who developed AE (AE group) and those who didn't (non-AE group), and between patients who survived after AE (alive group) and those who died after AE (dead group), and identified variables significantly associated with AE occurrence and survival using Cox hazards analyses. Results: Thirty-six (60%) were female. Twenty-two (36.7%) developed AE and seven of them (11.7%) died with the mean follow-up period of 2.7 years. The mean age at RA diagnosis was 61.1±16.3 years in AE group and 61.5±13.1 years in non-AE group. Sex, smoking habit and high-resolution computed tomography (HRCT) pattern were not significantly different between two groups. Although there was no significant difference, more patients in AE group received methotrexate (MTX) treatment than those in non- Background: A rapid and meaningful reduction in pain is important to quality of life in patients (pts) with rheumatoid arthritis (RA). Baricitinib (bari) is a selective inhibitor of Janus kinase (JAK)1/JAK 2 in development for pts with active RA.
1 Objectives: To evaluate the effect of bari treatment on pain reduction compared to adalimumab (ADA) or placebo (PBO) in pts with inadequate response to methotrexate (MTX) or biologic disease-modifying antirheumatic drugs (bDMARDs). Methods: In RA-BEAM (NCT01710358), 1305 patients with inadequate response to MTX were randomised 3:3:2 to PBO QD, bari 4 mg once daily (QD), or ADA 40 mg biweekly. 2 In RA-BEACON (NCT01721044), 527 pts with inadequate response or intolerance to bDMARDs were randomised 1:1:1 to PBO or bari (2 or 4 mg) QD. 3 This post-hoc analysis reports the pts' assessment of pain using a visual analogue scale (VAS, range: 0 to 100 mm). The proportion of pts who achieved pain improvement of ≥30%, ≥50%, and ≥70% of their baseline pain at 1, 2, 4, 8, 12, 16, 20, and 24 weeks of treatment were compared between treatment groups using logistic models adjusted for geographic region, baseline pain score, baseline joint erosion status (RA-BEAM only), and history of bDMARD at screening (RA-BEACON only). Missing data were imputed using modified last observation carried forward. Results: Mean baseline pain scores were 60, 62, and 61 for PBO, bari 4 mg, and ADA, respectively, in RA-BEAM and 65, 62, and 66 for PBO, bari 2 mg, and bari 4 mg, respectively, in RA-BEACON. A significantly greater proportion of pts treated with bari 4 mg achieved ≥30% and ≥50% pain improvement as early as week 1 compared to PBO (both studies) and as early as week 4 compared to ADA (RA-BEAM) (Table) . A significant pain improvement of ≥70% was achieved at week 12 for pts treated with bari 4 mg compared to PBO (both studies) and ADA (RA-BEAM). Pain improvement of ≥30%, ≥50%, and ≥70% with bari 2 mg was significant compared to PBO by week 12 (RA-BEACON). Significant improvements in pain for bari vs PBO and bari vs ADA were sustained through week 24. Conclusions: Bari-treated pts reported significantly greater and more rapid reductions in pain severity as measured by the pain VAS compared to PBO or ADA; improvements were sustained through 24 weeks. The results were similar regardless of the pt population.
